Regeneron Pharmaceuticals, Inc. (REGN) Rating Reiterated by Canaccord Genuity

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)‘s stock had its “buy” rating reissued by stock analysts at Canaccord Genuity in a report issued on Monday. They currently have a $522.00 price target on the biopharmaceutical company’s stock. Canaccord Genuity’s price objective suggests a potential upside of 17.44% from the company’s current price.

Several other equities research analysts have also weighed in on REGN. BMO Capital Markets lifted their price objective on Regeneron Pharmaceuticals from $412.00 to $421.00 and gave the stock a “hold” rating in a report on Monday, May 15th. Cowen and Company reissued a “hold” rating and issued a $380.00 price objective on shares of Regeneron Pharmaceuticals in a report on Monday, May 15th. Credit Suisse Group reaffirmed a “buy” rating and set a $485.00 target price on shares of Regeneron Pharmaceuticals in a report on Monday, May 15th. Vetr lowered Regeneron Pharmaceuticals from a “sell” rating to a “strong sell” rating and set a $368.84 target price for the company. in a report on Monday, May 15th. Finally, Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Regeneron Pharmaceuticals in a report on Thursday, May 25th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $496.35.

Regeneron Pharmaceuticals (NASDAQ REGN) opened at 444.48 on Monday. The firm has a market capitalization of $47.13 billion, a P/E ratio of 44.59 and a beta of 1.65. Regeneron Pharmaceuticals has a 1-year low of $325.35 and a 1-year high of $543.55. The company has a 50 day moving average of $481.42 and a 200 day moving average of $444.42.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share for the quarter, topping the consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The company had revenue of $1.47 billion during the quarter, compared to analyst estimates of $1.36 billion. During the same quarter last year, the firm posted $2.82 EPS. The firm’s revenue for the quarter was up 21.2% on a year-over-year basis. On average, equities research analysts anticipate that Regeneron Pharmaceuticals will post $14.90 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This article was published by Ticker Report and is the property of of Ticker Report. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://www.tickerreport.com/banking-finance/2887510/regeneron-pharmaceuticals-inc-regn-rating-reiterated-by-canaccord-genuity.html.

In other Regeneron Pharmaceuticals news, CFO Robert E. Landry sold 189 shares of the business’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total value of $94,700.34. Following the completion of the sale, the chief financial officer now owns 10,099 shares in the company, valued at $5,060,204.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman P Roy Vagelos sold 15,191 shares of the business’s stock in a transaction that occurred on Friday, August 18th. The shares were sold at an average price of $470.15, for a total value of $7,142,048.65. Following the completion of the sale, the chairman now owns 329,543 shares of the company’s stock, valued at approximately $154,934,641.45. The disclosure for this sale can be found here. Insiders sold 129,257 shares of company stock valued at $61,745,394 in the last quarter. Corporate insiders own 10.40% of the company’s stock.

A number of hedge funds have recently made changes to their positions in REGN. BlackRock Inc. lifted its position in Regeneron Pharmaceuticals by 3,331.5% in the first quarter. BlackRock Inc. now owns 6,146,861 shares of the biopharmaceutical company’s stock valued at $2,381,971,000 after purchasing an additional 5,967,733 shares during the last quarter. Janus Henderson Group PLC lifted its position in Regeneron Pharmaceuticals by 15,495.4% in the second quarter. Janus Henderson Group PLC now owns 1,562,970 shares of the biopharmaceutical company’s stock valued at $767,637,000 after purchasing an additional 1,552,948 shares during the last quarter. Jennison Associates LLC lifted its position in Regeneron Pharmaceuticals by 74.1% in the second quarter. Jennison Associates LLC now owns 1,292,863 shares of the biopharmaceutical company’s stock valued at $634,977,000 after purchasing an additional 550,247 shares during the last quarter. Janus Capital Management LLC lifted its position in Regeneron Pharmaceuticals by 58.5% in the first quarter. Janus Capital Management LLC now owns 1,317,162 shares of the biopharmaceutical company’s stock valued at $510,406,000 after purchasing an additional 486,119 shares during the last quarter. Finally, Wellington Management Group LLP lifted its position in Regeneron Pharmaceuticals by 7.9% in the first quarter. Wellington Management Group LLP now owns 6,135,559 shares of the biopharmaceutical company’s stock valued at $2,377,590,000 after purchasing an additional 446,850 shares during the last quarter. Hedge funds and other institutional investors own 67.96% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.